Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study

OBJECTIVE: To examine the effect of certolizumab pegol (CZP) on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) patients with and without prior tumor necrosis factor (TNF) inhibitor exposure. METHODS: The ongoing phase III RAPID-PsA trial was double blind and placebo controlled to week...

Descripción completa

Detalles Bibliográficos
Autores principales: Gladman, D, Fleischmann, R, Coteur, G, Woltering, F, Mease, P J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171746/
https://www.ncbi.nlm.nih.gov/pubmed/24339179
http://dx.doi.org/10.1002/acr.22256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171746/
https://www.ncbi.nlm.nih.gov/pubmed/24339179
http://dx.doi.org/10.1002/acr.22256

Ejemplares similares